Pages that link to "Q30434700"

The following pages link to Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis (Q30434700):

Displaying 36 items.

• Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies (Q24645225) (← links)
• Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies (Q25257717) (← links)
• Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer (Q28396304) (← links)
• Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. (Q33159653) (← links)
• Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors (Q33372951) (← links)
• Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339) (Q33382525) (← links)
• A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) (Q33394153) (← links)
• A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (Q33430874) (← links)
• Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). (Q33439382) (← links)
• Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer (Q34079286) (← links)
• Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib (Q34294361) (← links)
• The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer (Q35001441) (← links)
• Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine (Q35066769) (← links)
• The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1. (Q35194201) (← links)
• Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs (Q36085634) (← links)
• Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies (Q36264209) (← links)
• Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells (Q36268729) (← links)
• The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma (Q37140809) (← links)
• Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner (Q37289335) (← links)
• Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. (Q37326210) (← links)
• The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. (Q37360220) (← links)
• NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia (Q37605861) (← links)
• Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications (Q37877012) (← links)
• Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. (Q37882459) (← links)
• Nuclear factor-κB: a key regulator in health and disease of lungs (Q37904904) (← links)
• Emerging role of immunoproteasomes in pathophysiology (Q38837519) (← links)
• 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways (Q38915333) (← links)
• MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic (Q39101546) (← links)
• Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells (Q39987026) (← links)
• Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells (Q44006947) (← links)
• Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. (Q45976336) (← links)
• The nuclear factor-kappa B pathway and response to treatment in breast cancer (Q47813995) (← links)
• 2005 highlights from: 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2005. (Q50767433) (← links)
• Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe? (Q89634774) (← links)
• The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer (Q92980454) (← links)
• Wikidata:Database reports/Constraint violations/P304 (← links | edit)